Pre-IPO HighTide Therapeutics (PHIP Updates) - Some Shareholders Have Chosen to Quit in Advance
Due to cash shortages and uncertainty in R&D/commercialization, HighTide faces big risks. Many original shareholders cashed out in advance,...
372 Views
HighTide Therapeutics (君圣泰医药) Pre-IPO: Unconvincing Bet on NASH
HighTide is looking to raise up to USD200 million via a Hong Kong listing. We analyzed the core product, HTD1801, as well as the pre-IPO investors...
340 Views
ECM Weekly (12th Nov 2023)-Renesas, Bajaj, Alchip, Hybe, Will, Wuxi, ChaPanda, Chenqi, Cello, Honasa
Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
527 Views
Pre-IPO HighTide Therapeutics - Its Outlook in NASH Field Is Not Optimistic, with High Risks
Intercept's failure to obtain FDA approval for NASH drug may cast shadow on HighTide's core product outlook.HighTide's valuation performance is...
331 Views
No more insights